Teosyal RHA 4 2x1ml
Important Notice
Regulated medical device (EU MDR 2017/745). For sale exclusively to qualified healthcare professionals.
What this purchase includes
- Original productFrom the manufacturer or an official distributor, CE marked.
- Batch and expiry documentedRecorded per unit on the delivery note and the invoice.
- Controlled storageOur own Madrid warehouse, 12 to 18 °C under 24 h control.
- Dispatch in 24 to 48 hFrom Madrid, insured and with a tracking number.
- Reachable Monday to Friday9:00 to 17:00 by WhatsApp and email. People, not forms.
Teosyal RHA® 4 is the most cross-linked reference of the Resilient Hyaluronic Acid range and the one with the greatest structural capacity: 23 mg/ml of hyaluronic acid intended for deep wrinkles in areas of thick skin and for remodelling of the facial contour. It is presented in 1.2 ml syringes — not 1 ml as in RHA 1, 2 and 3 — and it is the reference with the longest estimated duration in the range, between 15 and 18 months.
- HA 23 mg/ml
- Cross-linking < 5 % (NMR), the highest in the RHA range
- Lidocaine 0.3 % (3 mg/ml)
- Contents 2 syringes × 1.2 ml
- Needles 4 × 27G ½"
- Duration 15–18 months
Composition and technology
- Cross-linked hyaluronic acid: 23 mg/ml.
- Degree of cross-linking: < 5 %, measured by nuclear magnetic resonance. It is the most cross-linked reference of the RHA range (FDA, Summary of Safety and Effectiveness Data P170002), which translates into the firmest gel with the greatest capacity for projection of the four.
- Lidocaine hydrochloride: 0.3 % by mass (3 mg/ml).
- Residual BDDE: < 1 ppm.
- Phosphate buffer pH 7.3 q.s. for 1.2 ml.
- RHA technology (Resilient Hyaluronic Acid): Teoxane's patented manufacturing process (Preserved Network Technology) that applies minimal chemical modification and preserves the long hyaluronic acid chains. The result is a gel of low cross-linking (< 5 %) able to stretch and recover its shape with facial movement, instead of resisting it like a conventional rigid gel.
- Difference from a classic volumiser: RHA 4 achieves structural firmness while maintaining a chemical modification below 5 %, whereas the cross-linked PureSense range declares up to 10 %. It is the option where projection is required in an area that nevertheless remains mobile.
Position within the Teosyal RHA range
| RHA 1 | HA 15 mg/ml · 1 ml · 30G ½" — superficial fine lines and skin quality · ≥ 12 months |
|---|---|
| RHA 2 | HA 23 mg/ml · 1 ml · 30G ½" — moderate wrinkles, midface and lips · 12–18 months |
| RHA 3 | HA 23 mg/ml · 1 ml · 27G ½" — deep wrinkles, midface volume and remodelling of the lower third · 12–18 months |
| RHA 4 (this product) | HA 23 mg/ml · 1.2 ml · 27G ½" — deep wrinkles in thick skin and remodelling of the facial contour · 15–18 months |
| RHA Kiss | HA 23 mg/ml · 0.7 ml · 30G ½" — perioral region and lips · 12–18 months |
All references of the RHA range share a degree of cross-linking below 5 %, determined by nuclear magnetic resonance, and 0.3 % lidocaine. Within that margin the cross-linking increases in steps: RHA 2 is the least cross-linked, RHA 3 occupies an intermediate position and RHA 4 is the most cross-linked (FDA, Summary of Safety and Effectiveness Data P170002). That progression determines the firmness of the gel, the needle gauge supplied and the injection depth.
Indications and treatment areas
Therapeutic indication: reconstructive surgery, filling of scar depressions and reconstruction of volumes lost through lipoatrophy.
Aesthetic indication: remodelling of the facial contour and correction of deep wrinkles and folds in areas of thick skin.
Unlike RHA 2 and RHA 3, the manufacturer's documentation does not list lip volume augmentation among the performances of RHA 4. For lips, RHA Kiss, RHA 2 or RHA 3 are the appropriate choices.
Technique and treatment protocol
- Injection plane: dermis, subcutaneous or supraperiosteal plane, according to the area treated.
- Needles included: 27G ½", two per syringe (4 per pack).
- Cannula: a valid alternative is a 25G blunt cannula; compatibility verified by the manufacturer with TSK 25G/50 mm.
- Maximum volume: 6 ml per session, according to the manufacturer's preclinical and clinical data.
- Estimated duration: between 15 and 18 months.
- Do not inject into the epidermis. Do not combine in the same session with peeling, laser or ultrasound.
Technical data
| Manufacturer | Teoxane SA (Laboratoires Teoxane), Geneva, Switzerland |
|---|---|
| Active substance | Cross-linked hyaluronic acid 23 mg/ml |
| Degree of cross-linking | < 5 % (NMR) — the highest in the RHA range |
| Anaesthetic | Lidocaine HCl 0.3 % by mass |
| Cross-linker | BDDE, residual < 1 ppm |
| Technology | RHA — Resilient Hyaluronic Acid |
| pH | 7.3 (phosphate buffer) |
| Presentation | 2 pre-filled syringes of 1.2 ml |
| Needles | 4 × 27G ½" (2 per syringe) |
| Compatible cannula | 25G (TSK 25G/50 mm verified) |
| Treatment plane | Dermis, subcutaneous or supraperiosteal |
| Estimated duration | 15–18 months |
| Classification | CE-marked medical device |
| Use | Qualified healthcare professionals only |
Storage and pack contents
- Storage: between 2 °C and 25 °C, protected from direct sunlight.
- Do not use after the expiry date stated on the pack.
- Sterile single-use product. Do not reuse or re-sterilise the syringe or the needles.
- The pack contains: 2 pre-filled syringes of 1.2 ml, 4 sterile 27G ½" needles, and two traceability labels per syringe — one to be given to the patient and one for the medical record.
Contraindications and warnings
Contraindications: skin disorders, inflammation or infection in or near the treatment area; allergy to hyaluronic acid and a history of severe allergy or anaphylactic shock; allergy to lidocaine or to amide-type local anaesthetics; recent peel, laser or ultrasound treatment; autoimmune diseases; heart disease or treatment with beta-blockers; hepatocellular insufficiency or treatment for liver disease; epilepsy; porphyria; pregnancy, breastfeeding and patients under 18 years of age.
Vascular warning: intravascular injection may cause vascular occlusion, ischaemia and necrosis of the treated area. In the most serious cases it may lead to visual disturbances or blindness and to cerebral ischaemia or haemorrhage. Never inject intravascularly.
Before injection: do not treat if a dental procedure has been performed in the previous 15 days; avoid aspirin, anti-inflammatory drugs, anticoagulants and vitamin E during the preceding week; avoid alcohol and intense sun exposure on the previous day and on the day itself; remove make-up completely.
After injection: during the first 12 hours, do not apply make-up or undertake intense exertion; during the following week, avoid alcohol, prolonged sun or UV exposure, temperatures below 0 °C, sauna and hammam; for 15 days, do not undergo dental procedures or other aesthetic treatments.
Always consult the instructions for use included in the pack before treatment.
Medical device intended exclusively for qualified healthcare professionals. Technical information based on the official documentation of Teoxane SA (instructions for use TEOSYAL RHA® 4, ref. 230582-00, and patient product information). This information sheet does not replace the instructions for use supplied with the product.